Results 91 to 100 of about 18,181 (226)

Production of a biosimilar version of aflibercept to improve VEGF blocker cytotoxicity on endothelial cells

open access: yes, 2023
This project aimed to produce a biosimilar version of aflibercept (AFL) and evaluate the effect of the co-treatment of AFL with other vascular endothelial growth factor (VEGF) blocker drugs.
Amin Ramezani (102884)   +4 more
core   +1 more source

Proteomic analysis in hidradenitis suppurativa reveals systemic inflammation in all disease stages

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Proteomic profiling reveals systemic inflammation in patients with hidradenitis suppurativa, even in early disease. Distinct mediators (e.g. TGF‐α, OSM, HGF) are elevated early, whereas others correlate with clinical severity (e.g. IL‐6, VEGF‐A, IL‐17A) or disease duration (e.g.
Lotta Sandelin Francke   +5 more
wiley   +1 more source

Biosimilars in pediatrics

open access: yesArchivos Argentinos de Pediatria
Biosimilars are highly similar versions of already authorized biological drugs. A notable benefit of these is their significantly lower price compared to innovator drugs, which frees up healthcare resources and improves affordability. Leading regulatory agencies approve biosimilars after rigorous comparability studies, ensuring that there are no ...
Paulo, Cáceres Guido   +1 more
openaire   +2 more sources

Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
No evidence of an increased risk of incident cancer or KC was observed with biologic versus non‐biologic systemic therapies or across the biologic classes evaluated. Abstract Background There are concerns that biologic therapies for psoriasis may increase cancer risk. Objectives To compare risks of (i) incident cancer excluding keratinocyte carcinomas (
Oras A. Alabas   +9 more
wiley   +1 more source

Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan

open access: yes, 2017
Hideaki Yoshimura, Masaaki Hotta, Takahisa Nakanishi, Shinya Fujita, Aya Nakaya, Atsushi Satake, Tomoki Ito, Kazuyoshi Ishii, Shosaku Nomura First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka ...
Ito T   +8 more
core  

Optimising the use of unaffordability as a ground for compulsory licensing in African patent systems

open access: yesThe Journal of World Intellectual Property, EarlyView.
Abstract Although competition law has widely examined the issue of excessive pricing, its treatment within the patent law framework remains underexplored. This article examines how national patent laws structure grounds for compulsory licensing to address unaffordable pricing (under varying terminology) and analyses their structural limitations, with a
Isaac Kundakogo Kunko
wiley   +1 more source

A practical guide about biosimilar data for health care providers treating inflammatory diseases

open access: yes, 2017
Joseph Markenson,1,2 Daniel F Alvarez,3 Ira Jacobs,4 Carol Kirchhoff5 1Department of Rheumatology, 2Department of Medicine, Hospital for Special Surgery, New York, NY, 3Pfizer Inc, Collegeville, PA, 4Pfizer Inc, New York, NY, 5Pfizer Inc ...
Jacobs I   +3 more
core  

Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab

open access: yes
A biosimilar medicine is a successor to a reference ('originator'/'original-brand') biologic medicine brought to market once the patent and exclusive marketing rights for the reference have expired.
Poetzl, Johann   +9 more
core   +1 more source

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

open access: yesActa Ophthalmologica, Volume 104, Issue 8, Page 926-939, December 2026.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car   +3 more
wiley   +1 more source

Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching

open access: yes
As of 31 December, 2023, 31 observational studies have been published, including a total of 6081 patients who underwent a switch from one biosimilar to another biosimilar of the same reference biologic.
Cohen, Hillel, Bodenmueller, Wolfram
core   +1 more source

Home - About - Disclaimer - Privacy